Febuxostat

This classification denotes a xanthine oxidase inhibitor and uricosuric agent with the molecular formula C16H16N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 101V0R1N2E, chemically known as 5-thiazolecarboxylic acid, 2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methyl- but generally known as febuxostat, which bears US NIH Compound Identifier 134018. European Medicines Agency schedules Febuxostat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25382. The term FEBUXOSTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., No. 1.2002, List 47). World Health Organization schedules febuxostat in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule febuxostat under HS 29341000 and SITC 51579. As of Q4 2014, FEBUXOSTAT remains the US FDA Preferred Term for this commodity. Febuxostat bears US NLM identifiers UMLS ID C2683462 and NCI Concept Code C65629. SMILES: S1C(NC(C1C(=O)O)C)C1CC(C(OCC(C)C)CC1)C#N.